# Nabriva Therapeutics plc

Nabriva Therapeutics plc is a company headquartered in Dublin, Ireland.

## Company overview

- **Legal name:** Nabriva Therapeutics plc
- **Former names in filing history:** Nabriva Therapeutics AG (2015-05-14 to 2017-07-10)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Dublin, Ireland
- **Incorporated in:** Ireland
- **Fiscal year end:** December 31
- **SEC CIK:** 0001641640

## About

Nabriva Therapeutics plc is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001641640, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2023-04-17, it reported annual revenue of USD 36,935,000; net income of USD -57,185,000; total assets of USD 31,765,000 for the fiscal period ended 2022-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2022 (period ended 2022-12-31)

- **Revenue:** $36.9M (USD 36,935,000)
- **Net income:** -$57.2M (USD -57,185,000)
- **Total assets:** $31.8M (USD 31,765,000)
- **Cash and equivalents:** $12.4M (USD 12,414,000)
- **Operating cash flow:** -$36.7M (USD -36,711,000)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $28.9M (USD 28,895,000)
- **Net income:** -$49.5M (USD -49,450,000)
- **Total assets:** $80.9M (USD 80,909,000)
- **Cash and equivalents:** $47.7M (USD 47,659,000)
- **Operating cash flow:** -$59.6M (USD -59,557,000)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $5.0M (USD 5,027,000)
- **Net income:** -$69.5M (USD -69,484,000)
- **Total assets:** $58.4M (USD 58,436,000)
- **Cash and equivalents:** $41.4M (USD 41,359,000)
- **Operating cash flow:** -$71.3M (USD -71,331,000)

### FY2019 (period ended 2019-12-31)

- **Revenue:** $9.5M (USD 9,481,000)
- **Net income:** -$82.8M (USD -82,764,000)
- **Total assets:** $94.1M (USD 94,113,000)
- **Cash and equivalents:** $86.0M (USD 86,019,000)
- **Operating cash flow:** -$71.9M (USD -71,892,000)

## Recent SEC filings

- Form 10-Q — filed 2023-10-19 — period 2023-06-30 — 10-Q
- Form 8-K — filed 2023-07-31 — period 2023-07-30 — FORM 8-K
- Form 8-K — filed 2023-07-24 — period 2023-07-21 — FORM 8-K
- Form 8-K — filed 2023-07-07 — period 2023-06-30 — FORM 8-K
- Form 8-K — filed 2023-06-01 — period 2023-05-25 — FORM 8-K
- Form 10-Q — filed 2023-05-22 — period 2023-03-31 — 10-Q
- Form 10-K — filed 2023-04-17 — period 2022-12-31 — 10-K
- Form 8-K — filed 2023-02-06 — period 2023-01-31 — FORM 8-K
- Form 8-K — filed 2023-01-20 — period 2023-01-15 — FORM 8-K
- Form 8-K — filed 2023-01-09 — period 2023-01-04 — FORM 8-K
- Form 8-K — filed 2022-11-28 — period 2022-11-28 — FORM 8-K
- Form 8-K — filed 2022-11-10 — period 2022-11-10 — 8-K

---

Updated: 2026-10-23T20:08:00Z

Canonical page: https://altss.com/profile/nabriva-therapeutics-plc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology